TNF Pharmaceuticals Inc. Expands into Cryptocurrency with Exclusive Global Rights to Light-Based Computing Technology

Reuters

2025/09/02

TNF Pharmaceuticals Inc. Expands into Cryptocurrency with Exclusive Global Rights to Light-Based Computing Technology

TNF Pharmaceuticals Inc. has announced a significant expansion into the technology sector by securing exclusive global rights to an innovative light-based computing accelerator for cryptocurrency applications. The company's new strategic partnership with LightSolver Ltd. aims to deploy the first laser-based processing unit, which is expected to outperform traditional computing systems, including quantum and supercomputing. This move positions TNF as a first mover in the burgeoning photonic computing and cryptocurrency infrastructure markets. As part of this expansion, TNF is also planning to change its corporate name to reflect its new direction. The company has secured a $7.0 million private placement financing deal, involving key stockholders, to support this venture. TNF is in advanced discussions to enhance its development and commercialization strategy for this cutting-edge technology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TNF Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-026167), on September 02, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2564388674"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564388674\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564388674?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-02 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564388674","market":"nz","top_or_hot":-1,"title":"TNF Pharmaceuticals Inc. Expands into Cryptocurrency with Exclusive Global Rights to Light-Based Computing Technology","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TNF Pharmaceuticals Inc. Expands into Cryptocurrency with Exclusive Global Rights to Light-Based Computing Technology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TNF Pharmaceuticals Inc. has announced a significant expansion into the technology sector by securing exclusive global rights to an innovative light-based computing accelerator for cryptocurrency applications. The company's new strategic partnership with LightSolver Ltd. aims to deploy the first laser-based processing unit, which is expected to outperform traditional computing systems, including quantum and supercomputing. This move positions TNF as a first mover in the burgeoning photonic computing and cryptocurrency infrastructure markets. As part of this expansion, TNF is also planning to change its corporate name to reflect its new direction. The company has secured a $7.0 million private placement financing deal, involving key stockholders, to support this venture. TNF is in advanced discussions to enhance its development and commercialization strategy for this cutting-edge technology.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TNF Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-026167), on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TNF Pharmaceuticals Inc. Expands into Cryptocurrency with Exclusive Global Rights to Light-Based Computing Technology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTNF Pharmaceuticals Inc. Expands into Cryptocurrency with Exclusive Global Rights to Light-Based Computing Technology\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-02 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      TNF Pharmaceuticals Inc. Expands into Cryptocurrency with Exclusive Global Rights to Light-Based Computing Technology\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TNF Pharmaceuticals Inc. has announced a significant expansion into the technology sector by securing exclusive global rights to an innovative light-based computing accelerator for cryptocurrency applications. The company's new strategic partnership with LightSolver Ltd. aims to deploy the first laser-based processing unit, which is expected to outperform traditional computing systems, including quantum and supercomputing. This move positions TNF as a first mover in the burgeoning photonic computing and cryptocurrency infrastructure markets. As part of this expansion, TNF is also planning to change its corporate name to reflect its new direction. The company has secured a $7.0 million private placement financing deal, involving key stockholders, to support this venture. TNF is in advanced discussions to enhance its development and commercialization strategy for this cutting-edge technology.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TNF Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-026167), on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL7YhzSN:1","article_id":"2564388674","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564388674","pubTimestamp":1756819802,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TNF Pharmaceuticals Inc. has announced a significant expansion into the technology sector by securing exclusive global rights to an innovative light-based computing accelerator for cryptocurrency applications. The company's new strategic partnership with LightSolver Ltd. aims to deploy the first laser-based processing unit, which is expected to outperform traditional computing systems, including quantum and supercomputing. This move positions TNF as a first mover in the burgeoning photonic computing and cryptocurrency infrastructure markets. As part of this expansion, TNF is also planning to change its corporate name to reflect its new direction. The company has secured a $7.0 million private placement financing deal, involving key stockholders, to support this venture. TNF is in advanced discussions to enhance its development and commercialization strategy for this cutting-edge technology.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药"},"translate_title":"TNF Pharmaceuticals Inc.进军加密货币领域，拥有基于光的计算技术的全球独家权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNFA":0.9},"content_text":"TNF Pharmaceuticals Inc. Expands into Cryptocurrency with Exclusive Global Rights to Light-Based Computing Technology\n    \n\n        TNF Pharmaceuticals Inc. has announced a significant expansion into the technology sector by securing exclusive global rights to an innovative light-based computing accelerator for cryptocurrency applications. The company's new strategic partnership with LightSolver Ltd. aims to deploy the first laser-based processing unit, which is expected to outperform traditional computing systems, including quantum and supercomputing. This move positions TNF as a first mover in the burgeoning photonic computing and cryptocurrency infrastructure markets. As part of this expansion, TNF is also planning to change its corporate name to reflect its new direction. The company has secured a $7.0 million private placement financing deal, involving key stockholders, to support this venture. TNF is in advanced discussions to enhance its development and commercialization strategy for this cutting-edge technology.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TNF Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-026167), on September 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}